			1/GB 03/02509
A. CLASSII IPC 7	FICATION OF SUBJECT MATTER C12Q1/48 G06F19/00 C12N9/ C07K14/00	12 C12N5/00	C07K16/00
According to	b International Patent Classification (IPC) or to both national classifi	cation and IPC	
	SEARCHED		
	ocumentation searched (classification system followed by classifica-	tion symbols)	
IPC 7			
·	tion searched other than minimum documentation to the extent that	such degreeonts are included to	the fields source and
Jocumentat	dou searched ones than ummind occomengation to the extent fra	such documents are included in	ne ieios searcheo
lectronic da	ata base consulted during the International search (name of data b	ase and, where practical, search	terms used)
EPO-In	ternal, WPI Data, BIOSIS, EMBASE		
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the re	elevant passages	Relevant to claim No.
	WO 01/44497 A (UNIV DUNDEE ;ALE	SSI DADIO	1_16
٩	(GB); BIONDI RICARDO (GB))	221 DVKIO	1-16, 35-42
	21 June 2001 (2001-06-21)		33 12
	cited in the application		}
	abstract; claims 1-63		
	figure 15		
	page 5, line 19 - line 30 page 7, line 16 - line 30; table	a 1	
	page 13, line 26 -page 14, line	7	
	page 16, line 25 -page 18, line	30	
	page 19. line 20 -page 20, line	2	
	page 27, line 13 - line 30		
	page 29, line 11 -page 30, line	10	
	page 31, line 1 - line 6		
	page 32, line 10 - line 17	9]
	page 36, line 9 -page 37, line 2 page 39, line 16 - line 23	4	
	page 41, line 16 - Time 23	5	
	page 43, line 8 - line 30	J	Ì
	page 10, 1110 c	-/	
X Funt	ner documents are listed in the continuation of box C.	X Patent family members	s are listed in annex.
Special ca	tegories of cited documents:	"T" later document published a	ter the International filing date
A" docume	ent defining the general state of the art which is not ered to be of particular relevance	cited to understand the pri	conflict with the application but nclple or theory underlying the
E" earlier d	focument but published on or after the international	Invention "X" document of particular relevant	vance; the claimed invention
filing d	ate	cannot be considered nov	el or cannot be considered to when the document is taken alone
which	nt which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified)	"Y" document of particular relev	vance; the claimed invention
O" docume	ent referring to an oral disclosure, use, exhibition or	document is combined wit	nvolve an inventive step when the hone or more other such docu-
other n P" docume later th	neans ant published prior to the international filing date but an the priority date claimed	ments, such combination in the art. *&" document member of the se	being obvious to a person skilled
	actual completion of the international search	Date of mailing of the interr	
2	5 February 2004		2 1. 06. 2004
	nailing address of the ISA	Authorized officer	
	European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk		
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Vanhalst, K	(
	1 44, 1.07 10/040 0010	1	

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, or the relevant passages	neisvant to claim No.
	page 45, line 19 -page 59, line 10	
A	WO 01/35316 A (RAMNARAYAN KALYANARAMAN; STRUCTURAL BIOINFORMATICS INC (US); HESS) 17 May 2001 (2001-05-17) abstract; claims 1-63 page 3, line 10 -page 9, line 19 page 36, line 10 - line 15 page 40, line 23 -page 41, line 25 page 50, line 25 -page 53, line 2	1-16, 35-42
A	WO 01/71347 A (GODDARD WILLIAM A III;VAIDEHI NAGARAJAN; FLORIANO WELY B; CALIFORNIA I) 27 September 2001 (2001-09-27) abstract; claims 1-35 examples 1-5 page 3, line 24 -page 12, line 14	1-16, 35-42
A	US 5 854 992 A (DEWITTE ROBERT S ET AL) 29 December 1998 (1998-12-29) abstract column 1, line 5 - line 13 column 2, line 23 - line 36 column 3, line 38 -column 5, line 31 column 8, line 29 -column 18, line 8 claims 1-10,12-18	1-16, 35-42
A	WO 02/22793 A (ABELL CHRISTOPHER; BLUNDELL TOM L (GB); ASTEX TECHNOLOGY LTD (GB);) 21 March 2002 (2002-03-21) abstract; claims 1-11 page 1, line 5 - line 7 page 3, line 12 -page 4, line 25 page 5, line 9 -page 7, line 22 page 8, line 5 - line 12 page 9, line 25 -page 10, line 9 page 11, line 10 - line 20 page 12, line 3 - line 13 page 15, line 1 - line 35 page 21, line 13 -page 33, line 26	1-16, 35-42
A	WO 98/41638 A (MEDICAL RES COUNCIL) 24 September 1998 (1998-09-24) cited in the application abstract; claims 1-36 page 2, line 11 - line 14 page 21, line 26 -page 22, line 15 page 25, line 15 - line 28 page 27, line 20 -page 25 page 29, line 30 -page 30, line 29	1-16, 35-42
	·	

WO 00/56864 A (BALENDRAN ANUDHARAN; UNIV DUNDEE (GB); ALESSI DARIO (GB); CURRIE R) 28 September 2000 (2000-09-28) abstract; claims 1-33 page 14, line 14 - line 27 page 19, line 5 - line 9 page 19, line 26 -page 20, line 10 page 24, line 15 - line 30 page 27, line 4 - line 12 page 28, line 1 - line 17 page 29, line 19 - line 30 page 30, line 20 - line 26 page 31, line 11 -page 32, line 5 page 32, line 15 - line 30 page 33, line 15 -page 30 US 6 387 641 B1 (BELLON STEVEN ET AL) 14 May 2002 (2002-05-14) abstract EP 1 096 014 A (AGOURON PHARMA) 2 May 2001 (2001-05-02) abstract page 3, line 28 -page 4, line 38 WO 00/70030 A (KINETIX PHARMACEUTICALS INC; ZHU XIAOTIAN (US)) 23 November 2000 (2000-11-23) abstract		citation of decument with indication where appropriate of the coloured appropriate	In:
DUNDEE (GB); ALESSI DARIO (GB); CURRIE R) 28 September 2000 (2000-09-28) abstract; claims 1-33 page 14, line 14 - line 27 page 19, line 5 - line 9 page 19, line 5 - line 9 page 24, line 15 - line 30 page 27, line 4 - line 17 page 28, line 1 - line 17 page 29, line 19 - line 30 page 30, line 20 - line 26 page 31, line 11 - page 32, line 5 page 32, line 15 - line 30 page 33, line 15 - page 30 US 6 387 641 B1 (BELLON STEVEN ET AL) 14 May 2002 (2002-05-14) abstract EP 1 096 014 A (AGOURON PHARMA) 2 May 2001 (2001-05-02) abstract page 3, line 28 -page 4, line 38 WO 00/70030 A (KINETIX PHARMACEUTICALS INC; ZHU XIAOTIAN (US)) 23 November 2000 (2000-11-23) abstract P,X BIONDI RICARDO M ET AL: "High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site" EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 21, no. 16, 15 August 2002 (2002-08-15), pages 4219-4228, XP002266843 ISSN: 0261-4189	Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
14 May 2002 (2002-05-14) abstract A EP 1 096 014 A (AGOURON PHARMA) 2 May 2001 (2001-05-02) abstract page 3, line 28 -page 4, line 38 A W0 00/70030 A (KINETIX PHARMACEUTICALS INC; ZHU XIAOTIAN (US)) 23 November 2000 (2000-11-23) abstract P,X BIONDI RICARDO M ET AL: "High resolution crystal structure of the human PDK1 35-42 catalytic domain defines the regulatory phosphopeptide docking site" EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 21, no. 16, 15 August 2002 (2002-08-15), pages 4219-4228, XP002266843 ISSN: 0261-4189	Α	DUNDEE (GB); ALESSI DARIO (GB); CURRIE R) 28 September 2000 (2000-09-28) abstract; claims 1-33 page 14, line 14 - line 27 page 19, line 5 - line 9 page 19, line 26 -page 20, line 10 page 24, line 15 - line 30 page 27, line 4 - line 12 page 28, line 1 - line 17 page 29, line 19 - line 30 page 30, line 20 - line 26 page 31, line 11 -page 32, line 5 page 32, line 15 - line 30	
2 May 2001 (2001-05-02) abstract page 3, line 28 -page 4, line 38 A WO 00/70030 A (KINETIX PHARMACEUTICALS INC ;ZHU XIAOTIAN (US)) 23 November 2000 (2000-11-23) abstract P,X BIONDI RICARDO M ET AL: "High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site" EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 21, no. 16, 15 August 2002 (2002-08-15), pages 4219-4228, XP002266843 ISSN: 0261-4189	A	14 May 2002 (2002-05-14)	1
;ZHU XIAOTIAN (US)) 23 November 2000 (2000-11-23) abstract P,X BIONDI RICARDO M ET AL: "High resolution crystal structure of the human PDK1 35-42 catalytic domain defines the regulatory phosphopeptide docking site" EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 21, no. 16, 15 August 2002 (2002-08-15), pages 4219-4228, XP002266843 ISSN: 0261-4189	А	2 May 2001 (2001-05-02) abstract	1
crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site" EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 21, no. 16, 15 August 2002 (2002-08-15), pages 4219-4228, XP002266843 ISSN: 0261-4189	A	;ZHU XIAOTIAN (US)) 23 November 2000 (2000-11-23)	1
	P,X	crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site" EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 21, no. 16, 15 August 2002 (2002-08-15), pages 4219-4228, XP002266843 ISSN: 0261-4189	
		·	
			·

International application No. PCT/GB 03/02509

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	_
1. X Claims Nos.: 17,18,37 because they relate to subject matter not required to be searched by this Authority, namely:	
Claim 17 and 18: Rule 39.1(i) PCT - Mathematical method Claim 37: Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy	
2. X Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210	
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
This international Searching Authority found multiple inventions in this international application, as follows:	İ
see additional sheet	
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:	
4. X No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.: 1-16, 38-42(fully); 33-37 (partially)	
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-16, 38-42 (fully); 33-37 (partially)

A method of selecting compounds modulating the activity of PDK1-like kinases, the compounds identified with the method and the use of these compounds.

2. Claims: 17-18 (fully)

A method to assess the activation state of a protein kinase, based on the structure coordinates.

3. Claims: 19-32 (fully); 33-37 (partially)

Mutated PDK1-like protein kinases, wherein specific residues of the hydrofobic pocket or phosphate binding pocket are mutated.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 33, 34 (in full); 35-37 (in part, in as far as referring back to claim 33)

Present claims 33, 34 (in full) and claims 35-37 (in part, in as far as referring back to claim 33) relate to a compound defined by reference to a desirable characteristic or property, namely "identified or identifiable by a method according to claims 1-16, 28 or 29"

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for no such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the screening methods per se.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Information on patent family members

						05/02505
Patent docume cited in search rep		Publication date		Patent family member(s)		Publication date
WO 0144497	A	21-06-2001	AU EP WO JP US	2187301 1234188 0144497 2003516760 2003143656	A2 A2 T	25-06-2001 28-08-2002 21-06-2001 20-05-2003 31-07-2003
WO 0135316	Α	17-05-2001	AU EP WO US	1760001 1228370 0135316 2003158672	A2 A2	06-06-2001 07-08-2002 17-05-2001 21-08-2003
WO 0171347	A	27-09-2001	AU EP WO US	5095501 1272839 0171347 2002099506	A1 A1	03-10-2001 08-01-2003 27-09-2001 25-07-2002
US 5854992	A	29-12-1998	EP JP WO US	1021780 2001501210 9813781 2002055536	T A1	26-07-2000 30-01-2001 02-04-1998 09-05-2002
WO 0222793	: A	21-03-2002	US AU EP WO US US	6484103 8607401 1317529 0222793 2003082773 2003014192	A A1 A1 A1	19-11-2002 26-03-2002 11-06-2003 21-03-2002 01-05-2003 16-01-2003
WO 9841638	3 A	24-09-1998	AU CA EP WO JP US	734754 6412498 2284119 0983363 9841638 2001516218 2003108971 6734001	A A1 A1 A1 T A1	21-06-2001 12-10-1998 24-09-1998 08-03-2000 24-09-1998 25-09-2001 12-06-2003 11-05-2004
WO 0056864	1 A	28-09-2000	EP WO JP	1165761 0056864 2002539780	A2	02-01-2002 28-09-2000 26-11-2002
US 6387641	В1	14-05-2002	US AU WO	2003096303 3114600 0036096	Α	22-05-2003 03-07-2000 22-06-2000
EP 1096014	4 A	02-05-2001	US AU AU CA EP JP US	6670167 756175 6807900 2325228 1096014 2001161387 2003235899	B2 A A1 A2 A	30-12-2003 09-01-2003 10-05-2001 11-05-2001 02-05-2001 19-06-2001 25-12-2003
WO 007003	9 A	23-11-2000	AU WO	5147700 0070030		05-12-2000 23-11-2000